OKYO Pharma Announces Chairman and Founder Acquires Shares
Rhea-AI Summary
OKYO Pharma (NASDAQ: OKYO) announced that Panetta Partners Limited, an entity in which Executive Chairman Gabriele Cerrone has a beneficial interest, acquired 82,018 ordinary shares on NASDAQ on November 21, 2025.
The purchase increases the Chairman's total holding to 10,464,695 shares. The company is developing urcosimod for neuropathic corneal pain (NCP), an ocular condition without an FDA-approved therapy.
Positive
- Insider purchase of 82,018 shares by Chairman
- Total holding increased to 10,464,695 shares
- Leadership signal could indicate confidence in urcosimod development
Negative
- None.
News Market Reaction 13 Alerts
On the day this news was published, OKYO gained 10.99%, reflecting a significant positive market reaction. Argus tracked a peak move of +18.2% during that session. Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $9M to the company's valuation, bringing the market cap to $90M at that time. Trading volume was elevated at 2.4x the daily average, suggesting notable buying interest.
Data tracked by StockTitan Argus on the day of publication.
LONDON and NEW YORK, Nov. 21, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, today announces that Panetta Partners Limited, an entity in which Gabriele Cerrone, Executive Chairman has a beneficial interest, has acquired 82,018 of the Company’s ordinary shares on NASDAQ, bringing his total holding to 10,464,695 shares.
About Urcosimod (Formerly called OK-101)
Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response, as well as on neurons and glial cells in the dorsal root ganglion. Urcosimod was developed using a membrane-anchored-peptide technology to produce a novel long-acting drug candidate for treating ocular diseases. Urcosimod has been shown to produce anti-inflammatory and pain-reducing activities in mouse models of dry eye disease and corneal neuropathic pain, respectively, and is designed to combat washout through the inclusion of the lipid anchor built into the drug molecule to potentially enhance the efficacy of urcosimod within the ocular environment. Urcosimod showed clear statistical significance in multiple endpoints in a 240-patient completed Phase 2, multi-center, double-masked, placebo-controlled trial to treat dry eye disease, and just completed a randomized, placebo-controlled, double-masked Phase 2 trial of urcosimod to treat neuropathic corneal pain.
About OKYO
OKYO Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain and dry eye disease, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and dry eye disease. A Phase 2 trial of urcosimod to treat neuropathic corneal pain patients was just completed by OKYO.
For further information, please visit www.okyopharma.com.
Inquiries:
| Business Development & Investor Relations | Paul Spencer | +44 (0)20 7495 2379 |
FAQ
What did OKYO Pharma announce on November 21, 2025 regarding insider buying?
Who owns the shares bought in the OKYO Pharma insider purchase (NASDAQ: OKYO)?
How many OKYO shares does Gabriele Cerrone hold after the November 21, 2025 purchase?
Does the OKYO insider purchase affect the development of urcosimod for NCP?
What does the OKYO (NASDAQ: OKYO) insider buy mean for investors short-term?
Where was the OKYO Pharma insider transaction executed and when was it announced?
